Merck Announces New Agreement with ADAP Crisis Task Force to Improve Access and Care for People Living with HIV
Adaptimmune Announces Changes to Board and Executive Leadership Team
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Adaptimmune Announces Delisting from Nasdaq
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Reports Q3 2024 Financial and Business Updates
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Adaptimmune to Participate in Two Bank Conferences this September
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
Adaptimmune Reports Q2 2024 Financial and Business Updates
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
US FDA approves Adaptimmune's gene therapy for rare type of cancer
STM Investors Have Opportunity to Join STMicroelectronics N.V. Fraud Investigation with the Schall Law Firm
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
Adaptimmune Reports Q1 2024 Financial and Business Updates
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Adaptimmune Therapeutics plc (ADAP) Q4 2023 Earnings Call Transcript
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma